ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, has reported positive feedback from user tests within digital pathology and continues to proceed with product development for this fast-growing market, which has been facilitated by an agreement with a large biobank.
Founded in 1983, based in Stockholm, Sweden, ContextVision is the global market leader within image enhancement and is a software partner to leading medical imaging manufacturers all over the world. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
The company is continuing its focus on developing AI-based decision support tools for cancer diagnosis. First in the pipeline is INIFY prostate for prostate diagnosis. During the first quarter of 2019, the company performed user tests with three additional pathology centers.
ContextVision also signed an agreement with one of the largest biobanks in the world, giving the company access to a large amount of structured data, images and associated clinical data that opens for several new research projects within cancer diagnostics for the company.
“Following our best year ever, sales continue to grow in Q1. The growth in this quarter is coming from our business in Asia.” … “This stable global growth is really created by successful long-term focus within our medical imaging business.”
“The feedback has been positive and we expect BETA-installations to take place this summer, it will be our entrance into this fast-developing market where we will expand and offer a portfolio with decision support tools.”
“The agreement with the biobank is a very important step for us, supporting our long-term strategy within cancer diagnostics. Extensive amount of data is fundamental to develop AI-based products and tools so this will be an important enabler for further development.” – Fredrik Palm, CEO of ContextVision